Medullary thyroid cancer (MTC) is a rare, neuroendocrine tumour (NET) of parafollicular C cells comprising 5-8% of all thyroid cancers with variable biological behaviour and prognosis [1] . Overall mean survival in MTC is 75-85% at 10 years [1] [2] [3] . Management of both hereditary (20-30%) and sporadic MTC is challenging due to early cervical lymph node metastases occurring in 50% of patients and distant metastases to the liver, lung and bones being found in 10-20% at diagnosis [1, 3] . MTC secretes several neuroendocrine peptides, of which calcitonin (Ct) and less-specific carcinoembryonic antigen (CEA) are useful tumour markers for diagnosis, surveillance and prognosis. Yet despite the high sensitivity of an elevated serum Ct value as a predictor of disease presence, MTC is an elusive and notoriously problematic tumour to image [1, 3] . Anatomy-based imaging with CT and MRI has exhibited limited sensitivity due to the frequent small size of the metastatic deposits. Although a variety of specific and nonspecific scintigraphic techniques such as 201 Tl, 99m Tc-sestamibi, 99m Tc-tetrofosmin, 131 I/ 123 I-metaiodobenzylguanidine, 99m Tc-(V)dimercaptosuccinic acid (DMSA), and 111 Inoctreotide have been used to image MTC, none has emerged as the imaging technique of choice [4, 5] . This raises the question as to why we have been unable to successfully image MTC.
The rarity of MTC implies that no single centre can collect a sufficient number of cases, and to date there have been no large, cooperative studies to establish optimal imaging protocols. It has become apparent that MTCs are a heterogeneous group of neoplasms, and the biological behaviour of one MTC may differ significantly from that of another. Imaging approaches that have proven successful, for example using 18 F-fluorodeoxyglucose (FDG) PET/CT in lymphoma and solid cancers and 111 In-octreotide for somatostatin receptor scintigraphy (SRS) in carcinoids, may be too simplistic an imaging approach for MTC, which often appears intermediate in biological behaviour between more aggressive neoplasms characterized by high Ki-67 indices, and hormonally active NETs in which FDG PET has limited value.
Genetic testing provides a valuable insight into the phenotypic expression of MTC. Genetic mapping has confirmed the central role of germline mutations of the rearranged during transfection (RET) protooncogene in the pathogenesis of inherited MTC and has shown that somatic RET mutations occur in 50-60% of patients with sporadic MTC, and there have been advances in our understanding of how activated RET tyrosine kinase signalling pathways affect tumour growth and angiogenesis [1, [6] [7] [8] . Insights from genetic testing allow informed management decisions. As an example, the dilemma of the timing of prophylactic thyroidectomy in multiple endocrine neoplasia type 2 (MEN2), an autosomal dominant syndrome with near-complete penetrance in C cell hyperplasia and evolution to MTC, has been somewhat clarified with the availability of risk stratification guidelines based upon mutation-specific classifications [9, 10] . The American Thyroid Association (ATA) risk level D, including all MEN2B mutations, predicts an aggressive disease course with recommended early thyroidectomy before the age of 1 year. Conversely, for risk level A mutations, surgery may be safely delayed beyond the age of 5 years if basal and stimulated Ct levels remain normal.
In the last decade the success of FDG PET/CT in oncology imaging, and the increasing availability of hybrid PET/CT and SPECT/CT cameras, has fuelled intense interest in the development of multiple alternative single-photon-emitting somatostatin analogues and non-FDG positron-emitting radiopharmaceuticals, which demonstrate increased sensitivity for imaging MTC and NETs [5] . Total thyroidectomy with prophylactic central neck dissection, with or without lateral compartment dissection of lymph nodes is potentially curative in 60% of N0 patients, but in N1 patients cure rates fall to around 10% [3] . To our knowledge, there are no studies of the use of either PET/CT or SPECT/CT for preoperative MTC staging, although unlike radioiodine imaging in welldifferentiated thyroid cancer, total thyroidectomy is not a prerequisite for successful imaging of in-situ or locoregional metastatic disease in MTC. As recurrence rates of MTC approach 50%, patients should be monitored after initial surgical management with Ct and CEA levels, including calculation of doubling times [1, 3, 9, 11] . Should tumour biomarkers indicate persistent or recurrent disease, accurate restaging of MTC is crucial in subsequent management, whether to pursue a surgically based approach in an attempt to control locoregional disease, or to identify the best time to switch to systemic therapy for distant metastatic disease.
Hybrid SPECT/CT has superior diagnostic performance for endocrine imaging in comparison to the older techniques of planar imaging and SPECT. A PubMed search (22 October 2011) for reports on endocrine scintigraphy SPECT/ CT revealed more than 115 articles on radioiodine, metaiodobenzylguanine, iodomethyl-norcholesterol, somatostatin receptor and parathyroid scintigraphy, compared to only 10 articles at the end of 2005. SPECT/CT allows precise localization and characterization of radiotracer uptake (Fig. 1) . To date there are no original studies concerning SPECT/CT imaging in MTC, probably reflecting the low incidence of this neoplasm, although a case report of a patient with paratracheal MTC recurrence characterized with 111 In-octreotide SPECT/CT has been published [12] , while another report of the detection of bone metastases in a patient with MEN2B using 99m Tc-(V)DMSA SPECT/CT [13] . Studies with newer somatostatin analogues such as 99m Tc-EDDA/ HYNIC-TOC have shown a sensitivity of 79.5% and a specificity of 83.3% for MTC [14] , and further investigations of these radiopharmaceuticals should be performed with SPECT/CT when possible to ensure the highest diagnostic performance.
The first reported use of FDG PET in MTC was in 1997 where tumour was localized in 7/8 patients (88%) [15] , while in a larger group of 85 patients with histological confirmation, FDG PET demonstrated a sensitivity (78%) equal to that of MRI (82%), and superior to those of CT (50%), DMSA (33%) and somatostatin scintigraphy (25%) [16] . Two studies showed that FDG PET/CT outperforms CT and MRI for the detection of neck and mediastinal disease, but is inferior to CT for the detection of lung and liver metastases, and to MRI for the identification of metastases to bone [17, 18] . Three studies have examined serum Ct levels and the likelihood of a positive FDG PET scan. In general a significant gain in sensitivity is seen at a threshold plasma Ct level of >1,000 pg/ml. Conversely, sensitivity is low at 0-37% when the plasma Ct level is <500 pg/ml [19] [20] [21] . One study showed the prognostic value of FDG PET with 6 of 11 PET-positive patients (55%) succumbing to their disease, and 13 of 14 PET-negative patients (93%) remaining disease-free with an average follow-up of 44 months [22] . From these few studies it appears that FDG PET and PET/CT have an overall sensitivity in the range 47-79% with a trend to lower disease detection rates in more recent studies [5] . Although the use of FDG has been a significant step forward in the detection of MTC recurrences, it may be the optimal imaging technique for only a subset of patients with MTC.
Two novel positron-emitting radiopharmaceuticals, 18 Ffluorodihydroxyphenylalanine (FDOPA) and 68 Ga-DOTAlabelled somatostatin analogues, have shown promise in providing higher detectability of MTC lesions than FDG PET. FDOPA is an amino acid-derived radiotracer which is taken up, stored and decarboxylated by tumours belonging to the APUD system [23] . It was initially developed for neurological scanning [24, 25] . In 2001 Hoegerle et al. compared the value of FDOPA PET with that of FDG PET, SRS and morphological tomography imaging (i.e. CT, MRI) in patients with MTC and elevated Ct levels [26] . The sensitivity of FDOPA PET (63%) was superior to those of FDG PET (44%) and SRS (52%) for detection of MTC lesions. Although the sensitivity of morphological imaging modalities was higher than that of functional imaging, the authors concluded that neither FDOPA nor morphological imaging alone achieves sufficient sensitivity and specificity to be used as a sole imaging modality in the assessment of patients with MTC. Among the functional imaging modalities, the superiority of FDOPA PET (Fig. 2) has been shown by several studies with a sensitivity ranging from 44% to 90% [26] [27] [28] [29] [30] [31] [32] . The results of these studies have also been confirmed in the preclinical setting: FDOPA small-animal PET was also found to be accurate for monitoring disease progression over time [33] .
In a recent study, Luster et al. [34] found that no patient with a basal Ct level less than 60 pg/ml was truly positive for MTC on FDOPA PET/CT, and conversely that no patient with a basal Ct level more than 120 pg/ml was truly negative for MTC on PET/CT. They reported a sensitivity and specificity of 100% for FDOPA PET/CT in patients with a basal [27, 30, 35] , it is assumed that the combination of the two radiopharmaceuticals would probably provide the highest diagnostic sensitivity and specificity [34] [35] , in particular in patients with short (<6 months) Ct doubling times [27] . FDOPA seems to provide more reliable prognostic information whereas FDG allows prognostic evaluation [36] .
To our knowledge there is only a single published study specifically aimed at assessing the role of PET/CT with 68 Ga-DOTA peptides in MTC. The authors compared the accuracy of 68 Ga-DOTATATE PET/CT and 18 F-FDG PET/ CT in 18 patients previously radically treated for MTC and showing increasing serum Ct levels [27] . Both tracers showed similar suboptimal sensitivity values (72.2% for DOTATATE, 77.8% for FDG) for the detection of recurrent MTC. The observation that 68 Ga-DOTA peptide PET/CT may be useful in MTC patients but may fail to delineate either the whole tumour burden or tumour lesions with variable expression of somatostatin receptors has also been shown in single MTC cases described in the literature in the context of a large population of patients with NET with the location of the primary tumour other than in the thyroid. For example, of the only two patients with MTC among a population of 51 patients with NET with a nonthyroid primary, DOTATATE uptake was evident in one of the patients with an intermediate differentiation grade and absent in the other patient with a low differentiation grade [37] . The most relevant factor limiting MTC imaging with 68 Ga-DOTA peptides is the well-known lower incidence, variable density and an inhomogeneous pattern of somatostatin receptor expression on MTC cells [38, 39] . Therefore the effective clinical impact of 68 Ga-DOTA peptides in the diagnosis of MTC lesions remains controversial. However, it is important to underline that the confirmation of somatostatin receptors on MTC lesions in patients positive on 68 Ga-DOTA peptide PET may provide the indication to start radionuclide-targeted therapy that has been reported to be associated with a longterm survival benefit [40] . 68 Ga-DOTA peptide PET positivity would suggest an increased likelihood of the efficacy of 177 Lu-or 90 Y-labelled somatostatin analogue radionuclide therapy.
11 C-methionine PET has also been used to image MTC, although the reported lesion-based sensitivity of 73% is similar to that of FDG PET (80%), and thus provides no clear advantage over FDG PET [41] .
Unlike initial surgical management, reoperation for recurrent MTC rarely normalizes serum Ct levels [42] and the availability of more sensitive radiopharmaceuticals for localizing distant metastatic spread would reduce morbidity related to furtive surgical management. The lack of efficacy of external beam radiation treatment [3, 43, 44] , the low chemotherapy response rates of only 10-20% [1, 45, 46] , and the modest impact of 131 I-or 90 Y-labelled targeted radionuclide therapies with response rates of approximately 30% [45] , provide great impetus for studies of novel multikinase inhibitors as new approaches to therapy [45, 46] . The present clinical guidelines recommend that kinase inhibitors are the preferred best "current practice" therapy for inoperable, progressive MTC and should be investigated in clinical trials [6, 9, 11] . These small-molecule inhibitors, which include vandetanib and sorafenib, block ATP at catalytic sites in the RET tyrosine kinase activation pathway and have been found to have modest efficacy for stabilization of aggressive disease [6] [7] [8] 47] . Vandetanib is the first kinase inhibitor, approved by the FDA in April 2011 [6, 48] , and is generally well tolerated although cardiovascular, dermatological, endocrine and gastrointestinal toxicities have been encountered [7] .
Eligibility for trials of kinase inhibitors is currently based on demonstrable macroscopic disease amenable to RECIST anatomical response assessment [8] . However, some patients with elevated and rapidly rising Ct levels, in whom the source(s) cannot be identified will fail to meet inclusion criteria. Reliance on decreasing tumour size as a marker of response fails to account for the presence of amyloid sheets, found in 60-80% of MTC tumours, which may persist despite a therapeutic response, so that drug efficacy is underestimated [1, 8, 43] . Recently published PERCIST criteria highlight the importance of including metabolic response criteria into clinical trials of anticancer drugs, as these are more closely correlated with therapeutic response and survival [48] . Metabolic response criteria using FDG PET in mouse models for predicting early therapeutic efficacy of vandetanib have been reported [49] . Resistance to kinase inhibitors, recognized as arising from tumour activation of alternative signalling pathways [7] , appears to account for decreased drug effect(s), and molecular imaging techniques may more reliably distinguish responders and nonresponders.
Management of MTC requires highly accurate staging and restaging imaging techniques to optimize treatment strategies. For determination of a surveillance strategy for both sporadic and hereditary MTC, we now have the toolset to characterize tumours. Genetic testing, histological differentiation and grade (Ki-67 indices) [31] , tumour secretogogues, and Ct and CEA levels and doubling times [1, 9] can be used to develop a phenotype model to tailor individualized treatment and imaging surveillance. Customized imaging approaches will determine which radiopharmaceutical (FDG or non-FDG, especially FDOPA) is optimal for PET imaging of a given patient with MTC. Conversely, these imaging studies will provide unique information on individual tumour phenotype expression, including lack of tumour avidity, which may reveal as much about tumour behaviour and prognosis as a positive study.
Thus, our early experience suggests that molecular imaging will play an increasingly important role in the development of successful imaging and treatment strategies in MTC.
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